Floatz Rating
D30/100
Confidence
Indicative
Sponsor
LI FENG
Modality
UNKNOWN
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07380230CT.gov Efficacy and Safety of Qibei Jiedu Formula for Preventing and Managing Acute Radiation Dermatitis in Breast Cancer Patients | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Radiodermatitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Qibei Jiedu Formula (this asset) | LI FENG | N/A | D · 30 |
| Olea Europaea Oil | Cairo University | P4 | BB |
| Urea | University of Brasilia | P3 | BB |
| Flosteron | Cairo University | P4 | BB |
| Chamomilla Recutita | University of Brasilia | P3 | BB |
| Mometasone | North Central Cancer Treatment Group | P3 | BB |
| Cicaderma | Centre Leon Berard | P3 | B |
| Imtenan Oil | German University in Cairo | P2 | B |
| Curcumin-Based Gel | Gary Morrow | P2 | B |
+24 more in the Radiodermatitis cohort
Other indications for Qibei Jiedu Formula
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | N/A | D · 26 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Qibei Jiedu Formula in Radiodermatitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/qibei-jiedu-formula-radiodermatitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →